No, Jardiance (empagliflozin) and dapagliflozin are not the same medication
Jardiance and dapagliflozin are two distinct SGLT2 inhibitors with different chemical structures, though they belong to the same drug class and share similar mechanisms of action. 1
Key Differences
Chemical Structure
- Jardiance contains empagliflozin as its active ingredient, with the chemical formula C23H27ClO7 and molecular weight of 450.91 1
- Dapagliflozin is a separate molecule with its own distinct chemical structure
- Both are SGLT2 inhibitors but are manufactured by different pharmaceutical companies
Clinical Effectiveness
While both drugs work through the same mechanism (inhibiting sodium-glucose cotransporter-2), recent evidence suggests potential differences in specific outcomes:
Cardiovascular outcomes: Most large-scale studies show comparable effectiveness between the two agents 2, 3. A Scandinavian cohort study of nearly 200,000 patients found similar risks for major cardiovascular events (HR 1.02), heart failure (HR 1.05), and serious renal events (HR 0.97) 2.
Heart failure with mildly reduced ejection fraction (HFmrEF): Recent 2026 data suggests empagliflozin may have advantages in this specific population, showing lower hazards for hospitalization (HR 0.61), HF exacerbation (HR 0.64), and all-cause mortality (HR 0.75) compared to dapagliflozin 4.
Atrial fibrillation prevention: Dapagliflozin demonstrated superior efficacy in preventing atrial fibrillation compared to empagliflozin 5.
Kidney outcomes: A Danish population study of over 50,000 patients found comparable 6-year risks for acute kidney injury, chronic kidney disease progression, and other renal endpoints between the two drugs 6.
Guideline Perspective
Both medications are endorsed by major cardiovascular societies as foundational therapy for heart failure with reduced ejection fraction, alongside ARNI/ACEi/ARB, beta-blockers, and mineralocorticoid receptor antagonists 7. Guidelines from the ADA/EASD and ESC recognize the SGLT2 inhibitor class as providing consistent cardiovascular and renal protection, with all agents showing significant reductions in heart failure hospitalization or cardiovascular death 8.
Clinical Bottom Line
Choose either medication based on specific patient factors:
- For patients with atrial fibrillation risk or history: Consider dapagliflozin given its superior AF prevention 5
- For patients with HFmrEF (LVEF 41-49%): Consider empagliflozin based on recent real-world data showing mortality and hospitalization benefits 4
- For most other indications: Either agent is appropriate, as they demonstrate comparable effectiveness for cardiovascular mortality, MACE, heart failure outcomes, and renal protection 2, 3
Both medications carry similar safety profiles, including risks of volume depletion, urinary tract infections, genital mycotic infections, and rare but serious complications like Fournier's gangrene and diabetic ketoacidosis 1.